Misonidazole

Misonidazole

SCHEMBL6680186

COCC(O)Cn1ccnc1[N+](=O)[O-].Cc1ncc([N+](=O)[O-])n1CCO

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.58
MAPK1 P28482 2/20 0.58
ALDH1A1 P00352 2/20 0.58
THRB P10828 2/20 0.58
TSHR P16473 1/20 0.58
KMT2A Q03164 2/20 0.48
CHRM1 P11229 1/20 0.47
ATM Q13315 1/20 0.47
GLA P06280 1/20 0.46
CA1 P00915 5/20 0.44
CA2 P00918 5/20 0.44
CA9 Q16790 5/20 0.44
CA12 O43570 4/20 0.44
SMN1; SMN2 Q16637 1/20 0.41
MAPT P10636 1/20 0.40
EGFR P00533 4/20 0.40
ERBB2 P04626 4/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Misonidazole SCHEMBL51943 0.83 KMT2A (0.66) LMNATHRBKMT2ACA1CA2
Metronidazole SCHEMBL9833775 0.77 LMNA (0.61) LMNAMAPK1ALDH1A1THRBTSHR
Metronidazole SCHEMBL21581878 0.77 LMNA (0.91) LMNAMAPK1ALDH1A1THRBTSHR
Metronidazole SCHEMBL17781913 0.76 LMNA (0.83) LMNAMAPK1ALDH1A1THRBTSHR
Metronidazole SCHEMBL29168722 0.76 LMNA (0.94) LMNAMAPK1ALDH1A1THRBTSHR
Metronidazole SCHEMBL21293782 0.76 LMNA (0.94) LMNAMAPK1ALDH1A1THRBTSHR
Metronidazole SCHEMBL9460595 0.76 LMNA (0.94) LMNAMAPK1ALDH1A1THRBTSHR
Metronidazole SCHEMBL5313560 0.76 LMNA (1.00) LMNAMAPK1ALDH1A1THRBTSHR
Metronidazole SCHEMBL2221140 0.76 LMNA (1.00) LMNAMAPK1ALDH1A1THRBTSHR
Metronidazole SCHEMBL9482744 0.76 LMNA (1.00) LMNAMAPK1ALDH1A1THRBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019165171-A2 COMPOUNDS AND METHODS USEFUL IN BRACHYTHERAPY NORTH CAROLINA STATE UNIVERSITY (US) 2019-08-29 WO disclosed
EP-1468688-A2 Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments Auckland Uniservices Limited (NZ) 2004-10-20 EP disclosed
US-20040192686-A1 Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments AUCKLAND UNISERVICES LIMITED (NZ) 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192686-A1 Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments NPM1, DUOX1, NOX5 LMNA 4583/4885MAPK1 2226/4885ALDH1A1 609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.